MA30981B1 - Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments - Google Patents
Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicamentsInfo
- Publication number
- MA30981B1 MA30981B1 MA31971A MA31971A MA30981B1 MA 30981 B1 MA30981 B1 MA 30981B1 MA 31971 A MA31971 A MA 31971A MA 31971 A MA31971 A MA 31971A MA 30981 B1 MA30981 B1 MA 30981B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- oxadiazol
- sulfonyl
- phenyl
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Virology (AREA)
Abstract
L'INVENTION PORTE SUR DES SULFONYL-PHÉNYL-OXADIAZOLONES ET SUR LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS MONTRANT UNE ACTIVITÉ AGONISTE DE PPARDELTA OU DE PPARDELTA ET PPARGAMMA. ON DÉCRIT DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE I, DANS LAQUELLE LES RADICAUX SONT TELS QUE DÉFINIS, ET LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DES PROCÉDÉS PERMETTANT DE LES PRÉPARER. LES COMPOSÉS SONT APPROPRIÉS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE TROUBLES DU MÉTABOLISME DES ACIDES GRAS ET DES TROUBLES DE L'UTILISATION DU GLUCOSE AINSI QUE DE TROUBLES DANS LESQUELS LA RÉSISTANCE À L'INSULINE EST MISE EN JEU ET LA DÉMYÉLINISATION ET AUTRES TROUBLES NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06025880A EP1932843A1 (fr) | 2006-12-14 | 2006-12-14 | Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30981B1 true MA30981B1 (fr) | 2009-12-01 |
Family
ID=37998695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31971A MA30981B1 (fr) | 2006-12-14 | 2009-06-10 | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments |
Country Status (24)
Country | Link |
---|---|
US (1) | US8173674B2 (fr) |
EP (2) | EP1932843A1 (fr) |
JP (1) | JP2010512352A (fr) |
KR (1) | KR20090087922A (fr) |
CN (1) | CN101558064A (fr) |
AR (1) | AR064299A1 (fr) |
AU (1) | AU2007331805A1 (fr) |
BR (1) | BRPI0720416A2 (fr) |
CA (1) | CA2672347A1 (fr) |
CL (1) | CL2007003614A1 (fr) |
CO (1) | CO6210729A2 (fr) |
CR (1) | CR10778A (fr) |
EC (1) | ECSP099409A (fr) |
MA (1) | MA30981B1 (fr) |
MX (1) | MX2009005535A (fr) |
NO (1) | NO20092293L (fr) |
PE (1) | PE20081404A1 (fr) |
RU (1) | RU2009126745A (fr) |
SV (1) | SV2009003293A (fr) |
TN (1) | TN2009000242A1 (fr) |
TW (1) | TW200843749A (fr) |
UY (1) | UY30783A1 (fr) |
WO (1) | WO2008071311A1 (fr) |
ZA (1) | ZA200903160B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2727373A1 (fr) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Sulfonamides n-heterocycliques anneles avec groupement de tete oxadiazolone, procedes pour leur preparation et leur utilisation comme medicaments |
EP2288607B1 (fr) * | 2008-06-09 | 2014-09-24 | Sanofi | Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
KR102062640B1 (ko) * | 2012-05-25 | 2020-01-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합된 아자데칼린 글루코코르티코이드 수용체 조절제 |
EP3371177A1 (fr) | 2015-11-02 | 2018-09-12 | Basf Se | Utilisation d'oxadiazoles substitués pour lutter contre les champignons phytopathogènes |
EP3165094A1 (fr) | 2015-11-03 | 2017-05-10 | Basf Se | Oxadiazoles substitués pour lutter contre les champignons phytopathogènes |
WO2017076740A1 (fr) | 2015-11-04 | 2017-05-11 | Basf Se | Utilisation d'oxadiazoles substitués pour lutter contre les champignons phytopathogènes |
KR20180083419A (ko) | 2015-11-19 | 2018-07-20 | 바스프 에스이 | 식물병원성 진균을 퇴치하기 위한 치환 옥사디아졸 |
WO2017085098A1 (fr) | 2015-11-19 | 2017-05-26 | Basf Se | Oxadiazoles substitués pour lutter contre des champignons phytopathogènes |
US10986839B2 (en) | 2016-04-11 | 2021-04-27 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
WO2017211652A1 (fr) | 2016-06-09 | 2017-12-14 | Basf Se | Oxadiazoles substitués pour lutter contre des champignons phytopathogènes |
WO2017211650A1 (fr) | 2016-06-09 | 2017-12-14 | Basf Se | Oxadiazoles substitués pour lutter contre des champignons phytopathogènes |
US20190322631A1 (en) | 2016-12-19 | 2019-10-24 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
EP3339297A1 (fr) | 2016-12-20 | 2018-06-27 | Basf Se | Oxadiazoles substitués pour lutter contre les champignons phytopathogènes |
WO2018183947A1 (fr) | 2017-03-31 | 2018-10-04 | Corcept Therapeutics, Inc. | Modulateurs du récepteur de glucocorticoïdes destinés au traitement du cancer du col de l'utérus |
WO2018219797A1 (fr) | 2017-06-02 | 2018-12-06 | Basf Se | Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes |
EP3642187A1 (fr) | 2017-06-19 | 2020-04-29 | Basf Se | 2-[[5-(trifluorométhyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acétamides pour lutter contre des champignons phytopathogènes |
WO2019002158A1 (fr) | 2017-06-30 | 2019-01-03 | Basf Se | Trifluorométhyloxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes |
US11076596B2 (en) | 2017-09-18 | 2021-08-03 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
EP3713936B1 (fr) | 2017-11-23 | 2021-10-20 | Basf Se | Trifluorométhyl-oxadiazoles substitués pour lutter contre les champignons phytopathogènes |
SG11202105770YA (en) | 2018-12-19 | 2021-07-29 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
WO2020132046A1 (fr) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
EP3927345A4 (fr) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | Utilisations thérapeutiques du rélacorilant, un modulateur du récepteur des glucocorticoïdes dérivé d'azadécaline fusionnée à une hétéroarylcétone |
KR102649355B1 (ko) * | 2020-03-31 | 2024-03-19 | 주식회사 엘지화학 | 췌도 이식 보호용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
DE10222034A1 (de) * | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
US20070105959A1 (en) * | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
DE10335449A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
DE602004004631D1 (de) * | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
-
2006
- 2006-12-14 EP EP06025880A patent/EP1932843A1/fr not_active Withdrawn
-
2007
- 2007-11-30 EP EP07846915.2A patent/EP2102198B1/fr active Active
- 2007-11-30 CN CNA2007800454445A patent/CN101558064A/zh active Pending
- 2007-11-30 WO PCT/EP2007/010390 patent/WO2008071311A1/fr active Application Filing
- 2007-11-30 RU RU2009126745/04A patent/RU2009126745A/ru not_active Application Discontinuation
- 2007-11-30 KR KR1020097012309A patent/KR20090087922A/ko not_active Application Discontinuation
- 2007-11-30 BR BRPI0720416-7A patent/BRPI0720416A2/pt not_active IP Right Cessation
- 2007-11-30 CA CA002672347A patent/CA2672347A1/fr not_active Abandoned
- 2007-11-30 JP JP2009540626A patent/JP2010512352A/ja not_active Abandoned
- 2007-11-30 AU AU2007331805A patent/AU2007331805A1/en not_active Abandoned
- 2007-11-30 MX MX2009005535A patent/MX2009005535A/es not_active Application Discontinuation
- 2007-12-12 TW TW096147333A patent/TW200843749A/zh unknown
- 2007-12-12 PE PE2007001772A patent/PE20081404A1/es not_active Application Discontinuation
- 2007-12-12 AR ARP070105563A patent/AR064299A1/es not_active Application Discontinuation
- 2007-12-12 UY UY30783A patent/UY30783A1/es not_active Application Discontinuation
- 2007-12-12 CL CL200703614A patent/CL2007003614A1/es unknown
-
2009
- 2009-05-07 ZA ZA200903160A patent/ZA200903160B/xx unknown
- 2009-05-07 CR CR10778A patent/CR10778A/es not_active Application Discontinuation
- 2009-06-05 CO CO09058528A patent/CO6210729A2/es not_active Application Discontinuation
- 2009-06-09 US US12/480,974 patent/US8173674B2/en not_active Expired - Fee Related
- 2009-06-10 SV SV2009003293A patent/SV2009003293A/es unknown
- 2009-06-10 MA MA31971A patent/MA30981B1/fr unknown
- 2009-06-12 EC EC2009009409A patent/ECSP099409A/es unknown
- 2009-06-12 TN TNP2009000242A patent/TN2009000242A1/fr unknown
- 2009-06-15 NO NO20092293A patent/NO20092293L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2672347A1 (fr) | 2008-06-19 |
US8173674B2 (en) | 2012-05-08 |
WO2008071311A1 (fr) | 2008-06-19 |
RU2009126745A (ru) | 2011-01-20 |
CN101558064A (zh) | 2009-10-14 |
AU2007331805A1 (en) | 2008-06-19 |
TW200843749A (en) | 2008-11-16 |
EP2102198B1 (fr) | 2015-02-25 |
EP1932843A1 (fr) | 2008-06-18 |
ECSP099409A (es) | 2009-07-31 |
TN2009000242A1 (en) | 2010-10-18 |
US20090298871A1 (en) | 2009-12-03 |
CR10778A (es) | 2009-06-24 |
NO20092293L (no) | 2009-09-08 |
ZA200903160B (en) | 2010-10-27 |
BRPI0720416A2 (pt) | 2013-12-31 |
UY30783A1 (es) | 2008-07-31 |
MX2009005535A (es) | 2009-06-05 |
AR064299A1 (es) | 2009-03-25 |
KR20090087922A (ko) | 2009-08-18 |
SV2009003293A (es) | 2009-10-27 |
PE20081404A1 (es) | 2008-11-04 |
CL2007003614A1 (es) | 2008-06-20 |
EP2102198A1 (fr) | 2009-09-23 |
CO6210729A2 (es) | 2010-10-20 |
JP2010512352A (ja) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
MA29807B1 (fr) | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. | |
MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
MA32323B1 (fr) | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques | |
MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
MA32705B1 (fr) | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation | |
MA27741A1 (fr) | Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments | |
MA31841B1 (fr) | Modulateurs du gpr40 à biphényle substitué | |
MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA33274B1 (fr) | Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
TW200602342A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
TW200621732A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
US20220313633A1 (en) | Pharmaceutical composition for preventing or treating bone diseases | |
FR2939135B1 (fr) | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
MA32506B1 (fr) | Nouveaux composes | |
MA29812B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques | |
MA30540B1 (fr) | Derives de quinolines et compositions pharmaceutiques de ces derives. | |
MA27738A1 (fr) | Dérivés de cycloalkyle 1,3-substitués contenant des groupes acides, principalement hétérocycliques, procédés de préparation correspondants et utilisation desdits dérivés en tant que médicaments | |
MA29811B1 (fr) | [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
MA30308B1 (fr) | Dérivés de benzoisoindole utilisés dans le traitement de la douleur |